FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research report issued to clients and investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($6.20) per share for the year, up from their previous forecast of ($6.31). The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.15) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical’s Q4 2024 earnings at ($1.31) EPS, Q1 2025 earnings at ($1.39) EPS, Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.27) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($5.17) EPS and FY2026 earnings at ($2.63) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the prior year, the firm posted ($2.23) earnings per share. The business’s quarterly revenue was up 42.3% compared to the same quarter last year.

RARE has been the topic of several other reports. Wells Fargo & Company raised their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Wedbush reiterated a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday. TD Cowen lifted their price target on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Piper Sandler upped their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Stock Up 4.0 %

Shares of Ultragenyx Pharmaceutical stock opened at $42.94 on Wednesday. The company’s fifty day simple moving average is $44.63 and its two-hundred day simple moving average is $49.59. Ultragenyx Pharmaceutical has a 12-month low of $37.02 and a 12-month high of $60.37. The firm has a market cap of $3.97 billion, a PE ratio of -6.64 and a beta of 0.58.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC increased its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 294 shares in the last quarter. Motley Fool Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 0.3% in the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after acquiring an additional 360 shares during the period. KBC Group NV raised its holdings in shares of Ultragenyx Pharmaceutical by 24.5% during the third quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 506 shares during the last quarter. M&T Bank Corp lifted its position in Ultragenyx Pharmaceutical by 8.1% during the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock valued at $388,000 after purchasing an additional 525 shares during the period. Finally, Amalgamated Bank boosted its holdings in Ultragenyx Pharmaceutical by 13.4% in the second quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 696 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.80% of the stock is currently owned by company insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.